Crizotinib in ALK -Rearranged Inflammatory Myofibroblastic Tumor
Dana-Farber Cancer Institute · Harvard University · +5 more institutions
Abstract
Inflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neoplasm characterized by a spindle-cell proliferation with an inflammatory infiltrate. Approximately half of IMTs carry rearrangements of the anaplastic lymphoma kinase (ALK) locus on chromosome 2p23, causing aberrant ALK expression. We report a sustained partial response to the ALK inhibitor crizotinib (PF-02341066, Pfizer) in a patient with ALK-translocated IMT, as compared with no observed activity in another patient without the ALK translocation. These results support the dependence of ALK-rearranged tumors on ALK-mediated signaling and suggest a therapeutic strategy for genomically identified patients with the aggressive form of this…
Citation impact
- FWCI
- 37.90
- Percentile
- 100%
- References
- 25
Authors
18- JEJames E. ButrynskiCorresponding
Dana-Farber Cancer Institute, Harvard University, Dana-Farber/Harvard Cancer Center
- DRDavid R. D’Adamo
Memorial Sloan Kettering Cancer Center
- JLJason L. Hornick
Harvard University, Brigham and Women's Hospital
- PDPaola Dal Cin
Brigham and Women's Hospital
- CRCristina R. Antonescu
Memorial Sloan Kettering Cancer Center
Topics & keywords
- Crizotinib
- Anaplastic lymphoma kinase
- Medicine
- ALK inhibitor
- Cancer research
- Neoplasm
- Pathology
- Gene rearrangement
- Good health and well-being